Will Oncology Be A Game Changer For Granules India In FY26? MD Krishna Chigurupati Shares

Описание: Granules India reported a strong quarter, with significant growth driven by its formulation business, which now constitutes 76% of total revenue. MD Krishna Chigurupati sheds light on the decline in API, particularly paracetamol, and said that it is expected to continue for 2-3 quarters before rebounding. The company aims for 15-20% annual growth and is expanding its footprint in high-volume products and oncology, while maintaining a stable debt-equity ratio.

#granulesindia #q1results2024 #oncology

--------------------------------------------------------------------------------------------------------------------------------------------------
For more videos subscribe to our channel:    / @ndtvprofitindia  
Visit NDTV Profit for more news: https://www.ndtvprofit.com/
Don't enter the stock market unaware. Read all Research Reports here: https://www.ndtvprofit.com/research-r...

Follow NDTV Profit here
Twitter:   / ndtvprofitindia   ,   / ndtvprofit  
LinkedIn:   / ndtvprofit  
Instagram:   / ndtvprofit  
Facebook:   / ndtvprofit